Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Aug 28, 2025. The company reported -HK$0.121 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.121.

Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?

According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.

What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,024,730,800 shares outstanding.

What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of -HK$0.121 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.068%.

Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?

Currently, no hedge funds are holding shares in HK:2252

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

-117.51%

Trailing 12-Months

Asset Growth

36.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H

Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.